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Purpose: To evaluate the effect of a new, prescription-only medical food supplement containing 
omega-3 and omega-6 essential fatty acids on dry eye signs and symptoms, with or without 
concomitant topical cyclosporine.
Methods: A total of 43 subjects were randomized and followed for 6 months. Group 1 (n = 23) 
was assigned to take two soft geltabs of the medical food supplement by mouth twice daily 
for 6 months. Group 2 (n = 20) was directed to take the medical food supplement in the same 
manner, along with topical cyclosporine, instilled twice daily during the last 3 months of the 
study. Subjects were evaluated at baseline, month 1, month 3, and month 6. Primary outcome 
measures included tear breakup time (TBUT), conjunctival staining, corneal staining, and 
change in subjective symptoms.
Results: Both groups had a statistically significant improvement in TBUT between baseline 
and month 6. In the food supplement only group, TBUT improved by 0.805 seconds from 
baseline to month 6. In the supplement/cyclosporine group, TBUT improved by 1.007   seconds 
from baseline. There was no statistically significant difference in TBUT between the two 
groups at baseline, month 3, or month 6. There were no significant differences in corneal or 
conjunctival staining between or within groups. Subjective symptoms were also improved in 
both groups.
Conclusion: Supplementation with the proper balance of omega-3 and omega-6 essential fatty 
acids improved TBUT and relieved patient symptoms. The addition of topical cyclosporine 
did not convey any statistically significant improvement in TBUT beyond that achieved by 
the supplement.
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Introduction
Dry eye syndrome is a multifactorial disease affecting the ocular surface. A key 
mechanism in the initiation of dry eye is tear hyperosmolarity, which then activates a 
cascade of inflammatory events on the ocular surface and in the tears, contributing to a 
cycle of inflammation of the lacrimal gland, instability of the tear film, and worsening 
symptoms.1,2
Between 14% and 33% of the population worldwide suffers from dry eye, making 
it a significant public health problem.1 Dry eye symptoms, which include discomfort 
and visual blurring, account for nearly half of all primary or secondary eye care 
complaints.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Risk factors that have been closely associated with dry eye 
include increasing age, female gender, androgen   deficiency, 
hormone replacement therapy, systemic antihistamine use, 
connective tissue disease, history of refractive surgery, 
vitamin A deficiency, and low dietary intake of omega-3 
and omega-6 fatty acids.3
An International Task Force (ITF) Delphi panel recom-
mended a 4-point severity scale for dry eye (which they 
termed “dysfunctional tear syndrome”), ranging from mild/
episodic (level 1) to severe (level 4).3 This scale was adopted 
by the International Dry Eye Workshop (DEWS), which 
added treatment recommendations. For level 2 severity 
(moderate dry eye with no corneal involvement and mild 
to no   conjunctival staining) and above, the DEWS report 
recommends one or more of the following treatments: 
unpreserved tears, gels, ointments, cyclosporine A (  Restasis®) 
(Allergan, Irvine, CA), secretagogues, topical steroids, and 
nutritional   support (omega-3 and omega-6 essential fatty 
acids [EFAs]).4   Additional interventions are recommended 
as signs and symptoms worsen at severity levels 3–4.
Restasis therapy, along with artificial tears, has become 
the leading treatment for patients with dry eye. Cyclosporine 
is an immunomodulator with anti-inflammatory effects. 
In the clinical trials that led to the United States Food 
and Drug Administration’s approval of Restasis, 59% of 
subjects achieved improvement from baseline Schirmer 
scores at 6 months,5 and additional clinical experience has 
subsequently demonstrated the benefits of treatment with 
topical cyclosporine.
Dietary supplementation with EFAs is among the treat-
ments suggested by the expert panels because research has 
shown a positive effect on dry eye.6
Omega-3 and omega-6 polyunsaturated EFAs are 
precursors of lipid mediators known as eicosanoids that play 
an important role in regulating inflammation. Eicosanoids 
derived from omega-3 are anti-inflammatory, while those 
derived from omega-6 are generally considered to be pro-
inflammatory. Supplementation or increased dietary intake of 
foods containing omega-3 EFAs has been recommended, for 
a range of health benefits, to balance out the more common 
omega-6 EFAs in the typical Western diet.
In the ocular setting, higher intake of omega-3 EFAs 
has been associated with decreased risk of age-related 
macular degeneration7 and dry eye.8 Studies have suggested 
that nutritional supplementation with omega-3 fatty acids 
is related to improvement in dry eye and may contribute 
to restoration of the lipid layer, decreased inflammation 
and apoptosis, and increased tear secretion.9–11 A recently 
published pilot study found that average tear production 
and tear volume was increased in a group of patients 
taking an omega-3 supplement containing both fish oil and 
flaxseed oil.12
The balance between omega-3 and omega-6 EFAs is 
important because they work synergistically.10 In fact, rat 
models have suggested that supplements which include a 
combination of omega-3 and omega-6 EFAs may be ideal.13,14 
Although omega-6 EFAs are considered pro-inflammatory, 
certain plant-based omega-6 EFAs, such as gamma-linolenic 
acid (GLA), also have anti-inflammatory properties. 
  According to Belch and Hill GLA elevates dihomo-g-linolenic 
acid concentrations, leading to an increased synthesis of 
1-series prostaglandins that have a negative feedback role in 
chronic inflammation.15
A number of studies have shown a relationship between 
certain plant-based omega-6 EFA supplementations and the 
improvement of signs and symptoms in ocular surface dis-
ease, including contact lens-associated dry eye,16 meibomian 
gland dysfunction,17 and Sjögren’s syndrome.18 Therapy with 
plant-based omega-6 and artificial tears has also been shown 
to reduce conjunctival inflammation in dry eye patients.19
This study was designed to evaluate the effect of a new, pre-
scription-only medical food supplement containing omega-3 
and plant-based omega-6 EFAs on dry eye signs and symp-
toms, with or without concomitant topical cyclosporine.
Materials and methods
This was a prospective, randomized trial conducted at two 
clinical sites.
To be enrolled in the study, patients had to have a diagnosis 
of ITF level 1 dry eye or worse, based on subjective symptoms 
and at least one of three clinical signs of dry eye: Sodium 
fluorescein corneal staining; lissamine green conjunctival 
staining; and/or tear breakup time (TBUT) ,3 seconds. 
Symptoms were elicited via a standardized Ocular Surface 
Disease Questionnaire (Paul M Karpecki, OD, Karpecki 
Resource Group, Lexington, KY).
Exclusion criteria included: use of any topical therapeutic 
ocular medications within 7 days or any anti-inflammatory 
medications, including corticosteroids or cyclosporine A, 
within 30 days of beginning the study; current use of any 
oral antihistamines or anti-inflammatory medications; active 
ocular infection, ocular disease (other than dry eye syndrome), 
or uncontrolled systemic disease; any change in contact lens 
type, solutions or rewetting drops within the past 30 days; 
history of adverse reaction to either of the study medications; 
and prior history of corneal surgery.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Use of artificial tears for dry eye management and contact 
lens wear were not considered to be inclusion or exclusion 
criteria. However, subjects who used tears or wore contact 
lenses were instructed to maintain their normal regimens 
throughout the study.
Once referred to the study, informed consent was obtained 
and subjects were randomized, using a random number 
generator, to one of two groups. Both groups were given 
a prescription-only medical food supplement, Tears Again 
HYDRATETM (OCuSOFT, Rosenberg, TX), consisting of 
four geltabs containing a total of 1000 mg of omega-3 EFAs 
derived from flaxseed oil and 500 mg of omega-6 EFAs 
(GLA) derived from evening primrose oil, both of which 
are microencapsulated in a proprietary liposome process 
designed to improve absorption. The amount of EFAs per 
food supplement serving is similar to that used in other 
research on evening primrose oil16 and identical to that used 
in other research on flaxseed oil.11
Initially, 56 subjects were enrolled. A total of 13 subjects 
dropped out of the study, only three of whom dropped out for 
reasons potentially related to the treatment. The reasons for 
dropout are identified in Table 1. Results were compiled 
for the remaining 43 subjects.
Group 1 (n = 23) was assigned to take two soft geltabs 
of the medical food supplement by mouth twice daily (four 
geltabs per day in all) for 6 months. Group 2 (n = 20) was 
directed to take the medical food supplement in the same 
manner, along with topical cyclosporine, instilled twice daily 
during the last 3 months of the study. The prescription food 
supplement was provided free of charge, and subjects were 
reimbursed for their purchase of topical cyclosporine. The 
study was compliant with Health Insurance Portability and 
Accountability Act privacy regulations.
Subjects in both groups were evaluated at baseline, 
month 1, month 3, and month 6. Primary outcome measures 
included TBUT, conjunctival staining, corneal staining, and 
change in subjective symptoms. The clinicians evaluating 
the outcome measures were not masked to the cyclosporine 
group. Visual acuity testing and refractions were performed at 
each visit. The subjective assessment of change in symptoms 
was administered at 6 months. In this subjective assessment, 
patients were asked whether they experienced worsening 
or no improvement in symptoms, some improvement, or 
moderate to marked improvement.
A corneal staining evaluation was performed 1 minute 
after wetting a strip with 1 mg of fluorescein dye and placing 
it into the eye. A cobalt blue filter on the slit lamp was used 
to visualize the staining pattern and tear breakup. Corneal 
staining was graded on a scale of 0–4. Grade 0 was considered 
0–2 punctate erosions in any two quadrants or less; Grade 1 
was superficial punctate erosions in two or more quadrants, 
or centrally that could be individually counted (minute/fine 
point erosions with defined borders, faint fluorescence or 
minimal scattered stippling); Grade 2 was larger punctate 
erosions with diffuse borders in one or more quadrants (bright 
fluorescence or moderate stippling, increased density and 
coverage); Grade 3 was considered confluence of the punctate 
erosions in one or more quadrants or centrally; Grade 4 was 
confluence of erosions in the central cornea or involving 50% 
or more of any quadrant.
Following the instillation of fluorescein dye, TBUT was 
defined as the first significant break in the fluorescein stain-
ing pattern of the tear film and was measured three times at 
every visit. TBUT was calculated using a stopwatch for a 
minimum of 2 minutes to a maximum of 3 minutes.
Conjunctival staining was performed 2 minutes after 
instilling a strip containing 1.5 mg of lissamine green dye 
into each eye, and graded on a scale of 0–4. Grade 0 was 
0–2 punctate erosions in up to two quadrants; Grade 1 was 
punctate erosions in one or more quadrants (.2 punctate ero-
sions); Grade 2 was moderate punctate erosions in one or more 
quadrants (.20 individually counted erosions); Grade 3 was 
confluence of the erosions in one or more quadrants (clumped 
punctuate erosions making it difficult to identify individual 
erosions); and Grade 4 was severe punctate erosions in one 
or more quadrants affecting .50% of any quadrant.
A two-tailed, paired t-test was used to determine whether 
there was a significant difference (P , 0.05) between base-
line and month 6 of the study for each of the two groups 
and whether there was any significant difference between 
the groups at month 6.
Results
Table 2 lists the baseline, month 3, and month 6 results 
for the primary outcome measures. Both groups had a 
Table 1 reasons for dropout
Reason Number of subjects
Poor compliance 6
Moved from area 2
Unrelated medical problems  
(back injury, sinus infection)
2
Upset stomach 1
headaches 1
Incompatibility of flaxseed oil with  
blood-thinner medication
1
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statistically significant improvement in TBUT between 
baseline and month 6. In the food supplement only group, 
TBUT improved by 0.805 seconds from baseline to month 6. 
In the   supplement/cyclosporine group, TBUT improved 
by 1.007 seconds from baseline. (Figure 1) There was no 
statistically significant difference in TBUT between the two 
groups at baseline, at month 3 (before the addition of topical 
cyclosporine therapy in group 2), or at the conclusion of the 
study at month 6. There were no significant differences in 
corneal or conjunctival staining between groups or within a 
group during the course of the study.
In their subjective responses, approximately half the sub-
jects in both groups reported moderate to marked improvement 
of symptoms between baseline and 6 months (Table 3).
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Figure 1 Improvement in TBUT (in seconds). Both groups had a similar and statistically significant improvement in TBUT from baseline to month 6. There is no statistically 
significant difference between the groups at any point (baseline, month 3, or month 6).
Abbreviation: TBUT, tear breakup time.
Table 2 Change in main outcome measures
Group 1:  
supplement only  
(n = 23)
P value Group 2:  
supplement +  
cyclosporine  
(n = 20)
P value Between-group   
P value
TBUT  
(seconds)
Baseline 0.652 0.583 0.838
Month 3 1.196 0.231 1.422 0.021 0.760
Month 6 1.457 0.558 1.590 0.653 0.780
Δ baseline to  
6 months
0.805 0.006 1.007 0.004
Corneal staining  
(0–4 scale)
Baseline 0.848 0.875 0.893
Month 3 0.739 0.328 0.650 0.165 0.700
Month 6 0.717 0.833 0.675 0.825 0.859
Δ baseline to  
6 months
−0.131 0.299 −0.200 0.248
Conjunctival staining  
(0–4 scale)
Baseline 1.130 1.300 0.548
Month 3 1.261 0.514 1.300 1.000 0.879
Month 6 1.391 0.492 1.575 0.142 0.487
Δ baseline to  
6 months
0.261 0.218 0.275 0.326
Note: The only statistically significant changes were the changes in tear breakup time in both groups from baseline to 6 months.
Abbreviation: TBUT, tear breakup time.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Discussion
These findings suggest that the medical food supplement 
alone improved TBUT and relieved patient symptoms. The 
addition of a commonly used therapy, topical cyclosporine, 
did not convey any statistically significant improvement 
in TBUT beyond that achieved by the supplement, at 
least during the 3-month period that group 2 used the 
Restasis drops.
Use of contact lenses, contact lens solution interactions, 
and artificial tear use patterns could be confounding factors. 
These were permitted during the study but not specifically 
analyzed, so it is not known whether there were any differ-
ences between the two groups or within a group in regard to 
contact lens wear or artificial tear usage.
The initial TBUT values in this study were quite low. 
Even after the modest improvement found in the study, 
the resulting TBUT values are still indicative of tear film 
  instability. It is unknown whether measurement error 
contributed to this improvement. Nevertheless, the fact 
that TBUT improvement was accompanied by subjective 
  symptom improvement suggests that the change in TBUT 
was clinically meaningful.
Some studies have suggested that the TBUT testing that 
is typically performed in clinical settings is not highly cor-
related with dry eye disease severity.20 TBUT is considered 
a significant sign in the ITF classification scheme for dry 
eye.3 New diagnostic tools that are under investigation or 
in the process of being launched commercially may provide 
additional insight into the effective management of dry eye. 
However, at the time of this study – and until such tools 
become widely available – TBUT is a reasonable tool for 
assessing dry eye in the clinical setting.
We believe there is sufficient evidence in the literature 
to suggest that the proper balance of omega-3 EFAs and 
the GLA form of omega-6 EFAs should play a role in the 
treatment of dry eye. More research remains to be done on 
the composition and bioavailability of EFA medical food 
supplements like the one studied here in order to confirm 
their role in the treatment of dry eye. A future masked, well 
controlled, prospective study would be useful to confirm 
our results.
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